DiaCarta test for novel coronavirus gets FDA clearance

LabPulse.com staff writers
Apr 8, 2020
2020 01 27 21 38 4451 Lab 2019 Coronavirus Test 400

The U.S. Food and Drug Administration (FDA) has granted DiaCarta emergency use authorization (EUA) for its polymerase chain reaction (PCR) test to detect the novel coronavirus.

The QuantiVirus test evaluates nasopharyngeal swabs, oropharyngeal swabs, and sputum samples for three different RNA-encoded genes of SARS-CoV-2: N, Orflab, and E.

DiaCarta can now manufacture 500,000 tests per week, according to the company. It plans to further expand manufacturing to up to four times its current scale to meet increased demand.

The QuantiVirus test previously received the European CE Mark.

Latest in FDA Clearance
Candida Candidiasis Social
FDA clears marketing T2 Biosystems Candida test for pediatrics
September 16, 2024
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Treponema pallidum, the bacteria that cause syphilis.
NowDiagnostics granted FDA marketing authorization for OTC syphilis test
August 16, 2024
Fda Sign Dc Social
Thermo Fisher gets FDA 510(k) clearance for HLA typing CDx
August 7, 2024
Related Stories
Dna Sequencing2 Social
Research and Development
DiaCarta presenting posters on xenonucleic acid technology at AACR 2023
Business Agreement Social
Mergers & Acquisitions
Liquid biopsy diagnostics firm DiaCarta going public on NYSE through SPAC
2021 01 08 22 20 9120 Cancer Cell Target2 400
Research and Development
DiaCarta, NCI to work on cancer detection technology
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in FDA Clearance
FDA clears marketing T2 Biosystems Candida test for pediatrics
By LabPulse.com staff writers
T2Candida Panel may get a boost.
September 16, 2024
Candida Candidiasis Social
BioMérieux receives 510(k) certification for antimicrobial testing system
By LabPulse.com staff writers
BioMérieux has received 510(k) clearance from the U.S. Food and Drug Administration for its Vitek Reveal AST system, which reports antimicrobial susceptibility testing (AST) results directly from positive blood cultures.
August 21, 2024
Sepsis Bacteria Social
NowDiagnostics granted FDA marketing authorization for OTC syphilis test
By LabPulse.com staff writers
NowDiagnostics has been granted de novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its First To Know over-the-counter (OTC) syphilis test.
August 16, 2024
Treponema pallidum, the bacteria that cause syphilis.
Thermo Fisher gets FDA 510(k) clearance for HLA typing CDx
By LabPulse.com staff writers
Thermo Fisher's SeCore CDx HLA A Sequencing System has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use as a companion diagnostic (CDx) with Adaptimmune's T-cell receptor therapy Tecelra for synovial sarcoma.
August 7, 2024
Fda Sign Dc Social
Labcorp gets FDA de novo authorization for solid tumor mutation liquid biopsy test
By LabPulse.com staff writers
Labcorp has received de novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its PGDx Elio Plasma Focus Dx kitted assay, a pan-solid tumor liquid biopsy test that enables tumor mutation profiling.
August 5, 2024
Fda Button Social
Thermo Fisher Scientific gets FDA 510(k) clearance for multiple myeloma precursor assays
By LabPulse.com staff writers
Thermo Fisher Scientific received an extended 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Optilite Freelite assays for evaluating monoclonal gammopathy of undetermined significance, a precursor to multiple myeloma.
July 29, 2024
Multiple Myeloma Social
Diasorin C. auris test gets FDA de novo authorization
By LabPulse.com staff writers
Diasorin has received de novo authorization from the U.S. Food and Drug Administration (FDA) for its test kit for Candida auris, a multidrug-resistant fungal pathogen common in healthcare settings.
July 16, 2024
Candida 3 D Social
FDA approves Lilly’s Alzheimer’s disease treatment
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Kisunla (donanemab) for the treatment of Alzheimer’s disease.
July 3, 2024
Amyloid Plaque Alzheimer2 Social
FDA greenlights BioMérieux's mini respiratory, sore throat panel for POC testing
By LabPulse.com staff writers
BioMérieux received special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel Mini respiratory viral and bacterial testing device designed for point-of-care (POC) testing.
June 28, 2024
Business Regulation Graphic Social Resized
FDA grants 510(k) clearance to Genetic Signature for parasitic GI infection kit
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Genetic Signature's EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated molecular workflow.
June 7, 2024
Lab Petri Microbiology Social
Roche garners FDA EUA for 4-in-1 respiratory panel
By LabPulse.com staff writers
Roche has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Cobas Liat SARS-CoV-2, influenza A/B, and RSV nucleic acid test.
June 10, 2024
Fda Sign Dc Social
Diasorin receives FDA 510(k) clearance for fungal infection panel
By LabPulse.com staff writers
Diasorin has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel developed for the firm's Liaison Plex system.
June 6, 2024
Fda Button Social
Page 1 of 8
Next Page